XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Agenus Inc

Announcement: AGEN 10-Q Quarterly Report

Agenus Inc, a leading immuno-oncology company, has recently announced several developments in its clinical and preclinical-stage cancer treatments. In particular, the company's botensilimab/balstilimab combination has demonstrated remarkable responses and survival benefits in patients with non-microsatellite instability-high colorectal cancer and recurrent platinum-resistant/refractory ovarian cancer. These results have been presented at several conferences, including the ASCO-GI and SGO 2023 Annual Meeting on Women’s Cancer. In addition, the FDA has granted Fast Track Designation for the botensilimab/balstilimab combination in the treatment of non-MSI-H/deficient mismatch repair metastatic colorectal cancer patients. Agenus is conducting global Phase 2 trials and expects to commence a Phase 3 trial in non-MSI-H colorectal cancer in 2023.

Furthermore, Agenus's shareholder recently received a dividend of approximately 5 million shares of its subsidiary MiNK Therapeutics’ common stock, providing opportunities for direct ownership and future growth.

Overall, these developments demonstrate Agenus's ongoing commitment to advancing its development programs and providing significant benefits to patients who have not responded to or failed other available treatments. However, as with all clinical developments, investors should bear in mind that there are risks and uncertainties inherent in drug development that could impact the ultimate success of these treatments.

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE

Form 8-K - Current report - Item 2.02 Item 9.01

$AGEN Reports Positive Clinical Results for Botensilimab/Balstilimab Combination in Non-MSI-H Colorectal and Recurrent Platinum-Resistant Ovarian Cancer Patients

Announcement: AGEN 8-K Special Filing

Form 8-K - Current report - Item 8.01 Item 9.01

Part 1: Analysis of Performance

Agenus Inc., a clinical-stage immuno-oncology company, has an extensive pipeline of immune modulatory antibodies, adoptive cell therapies, and vaccine adjuvants to fight cancer and infections. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. During the period under review, the company made significant progress in advancing its pipeline, with its lead program, botensilimab (AGEN1181), advancing in multiple clinical programs designed to support regulatory pathways for accelerated development. The company initiated worldwide trials for botensilimab in microsatellite stable colorectal cancer, melanoma, and pancreatic cancer in 2022. Also, the company formed collaborations with Bristol-Myers Squibb, Betta Pharmaceuticals Co. Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharpe & Dohme to develop and commercialize its products. 

Pursuant to the Betta License Agreement, the company received $15.0 million upfront and is eligible to receive up to $100.0 million in milestone payments plus royalties on any future sales in Greater China. In addition to this, the company remains eligible to receive up to $405.0 million and $76.5 million in potential development, regulatory, and commercial milestones from Incyte and Merck, respectively. 

However, the company announced the withdrawal of its biologics license application for balstilimab monotherapy to treat second-line cervical cancer, making it no longer pursuing U.S. registration for the combination of balstilimab and zalifrelimab in second-line cervical cancer, following the full approval of pembrolizumab. The termination of the OX40 program, effective October 2023, by Incyte also affected the company. 

Part 2: Forward Looking Analysis

Agenus Inc. has an extensive pipeline of immune modulatory antibodies, adoptive cell therapies, and vaccine adjuvants to fight cancer and infections, which are designed to drive success in I-O through speed, innovation, and effective combination therapies. The company's lead program, botensilimab, which is designed to support regulatory pathways for accelerated development, is advancing through multiple clinical programs worldwide. The company also has collaborations with Bristol-Myers Squibb, Betta Pharmaceuticals Co. Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharpe & Dohme, which could drive the development and commercialization of its products. 

Going forward, the company needs to focus on developing innovative products that could attract partners and investors. Also, it needs to keep up with its competitors by developing its existing products and advancing them through the clinical trials stage. The company also needs to focus on ways to manage risks, such as the termination of licensing agreements by its partners, which could affect its future performance. 

In conclusion, Agenus Inc. is a promising company with an extensive pipeline of innovative products, collaborations with industry experts, and a focus on driving success in I-O through speed, innovation, and effective combination therapies. It has made significant progress in advancing its lead program, botensilimab, but faces risks such as termination of licensing agreements by its partners. The company needs to focus on developing innovative products to attract partners and investors and managing risks to ensure future growth and success.

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Analysis of Agenus Inc. Performance & Collabs

Analyst Summary:

Agenus Inc. has reported its financial results for Q4 2022 and the full year, as well as a corporate update for 2023. The company has shown strong momentum across its diverse clinical pipeline of immuno-oncology programs, with anchor programs botensilimab and balstilimab demonstrating exciting potential in combination to treat treatment-resistant cancers. The development program for balstilimab in MSS CRC and other priority indications is underway. Data from the program has generated considerable interest from experts worldwide, with significant benefits compared to standard care and other investigational therapies in patients with treatment-resistant tumors. The company expects to complete dosing of the Phase 1b study for AGEN2373 (anti-CD137) and botensilimab in melanoma in H1 2023, with the potential launch of a design randomized phase 3 study if response rates persist. The company also expects to initiate combination cohorts of AGEN1571 (anti-ILT2) with botensilimab and balstilimab in 2023. The company's existing collaborations evaluating combinations of external agents with its PD-1 and CTLA-4 antibodies sponsored and executed by partners will also advance. The company reported a cash balance of $307 million as of December 31, 2021, and its revenue per share for the full year was $0.78. The company holds a suite of antibody discovery platforms and state-of-the-art GMP manufacturing facility. However, investors should be cautious as forward-looking statements included in the official release are subject to risks and uncertainties that could cause actual results to differ materially.

Announcement: AGEN 10-Q Quarterly Report

Announcement: AGEN 10-Q Quarterly Report

$AGEN Reports Positive Clinical Results for Botensilimab/Balstilimab Combination in Non-MSI-H Colorectal and Recurrent Platinum-Resistant Ovarian Cancer Patients

$AGEN Reports Positive Clinical Results for Botensilimab/Balstilimab Combination in Non-MSI-H Colorectal and Recurrent Platinum-Resistant Ovarian Cancer Patients

Announcement: AGEN 8-K Special Filing

Announcement: AGEN 8-K Special Filing

Announcement: AGEN 8-K Special Filing

Announcement: AGEN 8-K Special Filing

Analysis of Agenus Inc. Performance & Collabs

Analysis of Agenus Inc. Performance & Collabs

$AGEN reports strong clinical pipeline and potential in combination therapy.

$AGEN reports strong clinical pipeline and potential in combination therapy.